LFD

(1R)-1-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)ethyl {4-[4-(3,4-dichlorophenyl)piperazin-1-yl]phenyl}carbamate

Created:	2014-01-02
Last modified:	2014-07-30

Find Related PDB Entry
1 entries where LFD is found as a standalone ligand

Find related ligands:

Similar Ligands (Stereospecific) Similar Ligands (including Stereoisomers) Similar Ligands (Quick Screen) Similar Ligands (Substructure Stereospecific) Similar Ligands (Substructure including Stereoisomers)

Chemical Details
Formal Charge	0
Atom Count	64
Chiral Atom Count	1
Bond Count	68
Aromatic Bond Count	23

2D diagram of LFD

Toggle Hydrogen Toggle Labels

Chemical Component Summary
Name	(1R)-1-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)ethyl {4-[4-(3,4-dichlorophenyl)piperazin-1-yl]phenyl}carbamate
Systematic Name (OpenEye OEToolkits)	[(1R)-1-(2,4-dichlorophenyl)-2-imidazol-1-yl-ethyl] N-[4-[4-(3,4-dichlorophenyl)piperazin-1-yl]phenyl]carbamate
Formula	C₂₈ H₂₅ Cl₄ N₅ O₂
Molecular Weight	605.342
Type	NON-POLYMER

Chemical Descriptors
Type	Program	Version	Descriptor
SMILES	ACDLabs	12.01	Clc1ccc(cc1Cl)N5CCN(c2ccc(cc2)NC(=O)OC(c3ccc(Cl)cc3Cl)Cn4ccnc4)CC5
SMILES	CACTVS	3.385	Clc1ccc([CH](Cn2ccnc2)OC(=O)Nc3ccc(cc3)N4CCN(CC4)c5ccc(Cl)c(Cl)c5)c(Cl)c1
SMILES	OpenEye OEToolkits	1.7.6	c1cc(ccc1NC(=O)OC(Cn2ccnc2)c3ccc(cc3Cl)Cl)N4CCN(CC4)c5ccc(c(c5)Cl)Cl
Canonical SMILES	CACTVS	3.385	Clc1ccc([C@H](Cn2ccnc2)OC(=O)Nc3ccc(cc3)N4CCN(CC4)c5ccc(Cl)c(Cl)c5)c(Cl)c1
Canonical SMILES	OpenEye OEToolkits	1.7.6	c1cc(ccc1NC(=O)O[C@@H](Cn2ccnc2)c3ccc(cc3Cl)Cl)N4CCN(CC4)c5ccc(c(c5)Cl)Cl
InChI	InChI	1.03	InChI=1S/C28H25Cl4N5O2/c29-19-1-7-23(25(31)15-19)27(17-35-10-9-33-18-35)39-28(38)34-20-2-4-21(5-3-20)36-11-13-37(14-12-36)22-6-8-24(30)26(32)16-22/h1-10,15-16,18,27H,11-14,17H2,(H,34,38)/t27-/m0/s1
InChIKey	InChI	1.03	RKYWJGOKHMLHHS-MHZLTWQESA-N

Related Resource References

Resource Name	Reference
PubChem	76871875
ChEMBL	CHEMBL3318325

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.